(Vox) – No one wants to make it.

A new antiviral pill for dengue called mosnodenvir showed promising results in early phase 2 trials. In a study where volunteers were deliberately exposed to dengue, roughly half of those who received the highest dose never got sick at all. For a field that has struggled for decades to find an effective antiviral, it’s the clearest evidence yet that a drug can prevent dengue — and researchers believe the same pill could eventually treat people who are already infected.

But, even before the results were published, Johnson & Johnson, the American pharmaceutical giant that developed mosnodenvir, had already abandoned any efforts to bring the drug to market. (Read More)